| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
The primary target of coreoside B is bacteria. The compound shows weak antimicrobial activity against S. aureus and B. anthracis. Coreoside B also has anti-tumor, anti-inflammatory, immune-enhancing, antiviral, antioxidant, and anti-aging activities. The precise molecular targets and mechanisms of action have not been fully elucidated.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the biological activities of coreoside B. The compound shows weak antimicrobial activity against S. aureus and B. anthracis. Coreoside B also has anti-tumor, anti-inflammatory, immune-enhancing, antiviral, antioxidant, and anti-aging activities. These activities support its potential for further investigation.
|
| ln Vivo |
In vivo activity of coreoside B has not been extensively reported. The compound is primarily used as a research tool for in vitro studies. Animal model studies evaluating its in vivo efficacy have not been extensively published. Further studies are needed to assess its therapeutic potential.
|
| Enzyme Assay |
For antimicrobial activity screening, standard agar diffusion or broth microdilution methods are used. Bacteria are cultured on appropriate media and exposed to serial dilutions of coreoside B. MIC values are determined. Standard protocols for antimicrobial activity testing are described in the literature.
|
| Cell Assay |
For in vitro cell-based studies, bacterial cells are cultured in appropriate media and treated with serial dilutions of coreoside B. Bacterial growth is assessed. For anticancer studies, cancer cell lines may be treated with the compound. Standard protocols for these assays are described in the literature.
|
| Animal Protocol |
In vivo animal studies for coreoside B have not been extensively reported. For similar natural compounds, mouse models of infection, inflammation, or cancer may be used. The compound would be administered via oral or intraperitoneal routes. Standard protocols for in vivo efficacy studies can be adapted from the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of coreoside B have not been comprehensively characterized. As a glycoside with a molecular weight of 528.55 g/mol, it may have limited oral bioavailability. Specific PK parameters such as half-life and bioavailability have not been reported. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for coreoside B are limited. As a natural product, it may have a favorable safety profile. However, systematic toxicological studies have not been extensively published. The compound is for research use only and is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Coreoside B is a research compound used in studies of natural products and their biological activities. It is extracted from Coreopsis tinctoria Nutt. The compound has weak antibacterial activity and various other biological activities. No clinical trials or therapeutic applications have been reported.
|
| Molecular Formula |
C25H36O12
|
|---|---|
| Molecular Weight |
528.55
|
| Exact Mass |
528.22
|
| CAS # |
1580464-83-0
|
| PubChem CID |
155289777
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.45±0.1 g/cm3(Predicted)
|
| Boiling Point |
864.8±65.0 °C(Predicted)
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
37
|
| Complexity |
864
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O1[C@H](CO)[C@H]([C@@H]([C@H]([C@@H]1OC(CCO)CC/C=C/C#CC#C/C=C/CO)O[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)O)O
|
| InChi Key |
DJUIHAHXAHDXGQ-PABXJNOPSA-N
|
| InChi Code |
InChI=1S/C25H36O12/c26-12-9-7-5-3-1-2-4-6-8-10-16(11-13-27)35-25-23(21(32)20(31)18(14-28)36-25)37-24-22(33)19(30)17(29)15-34-24/h4,6-7,9,16-33H,8,10-15H2/b6-4+,9-7+/t16?,17-,18+,19-,20+,21-,22+,23+,24-,25+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S)-2-[(2R,3R,4S,5S,6R)-2-[(6E,12E)-1,14-dihydroxytetradeca-6,12-dien-8,10-diyn-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8920 mL | 9.4598 mL | 18.9197 mL | |
| 5 mM | 0.3784 mL | 1.8920 mL | 3.7839 mL | |
| 10 mM | 0.1892 mL | 0.9460 mL | 1.8920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
